Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings

AtriCure (ATRC) reported $134.27 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 15.8%. EPS of -$0.01 for the same period compares to -$0.17 a year ago.The reported revenue represents a surprise of +2.09% over the Zacks Consensus Estimate of $131.52 million. With the consensus EPS estimate being -$0.11, the EPS surprise was +90.91%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how AtriCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:United States Revenue- Pain management: $20.84 million versus the three-analyst average estimate of $20.59 million. The reported number represents a year-over-year change of +27.7%.International Revenue- Pain management: $2.08 million versus the three-analyst average estimate of $2.77 million. The reported number represents a year-over-year change of +30.8%.United States Revenue- Total ablation: $43.02 million compared to the $63.41 million average estimate based on three analysts. The reported number represents a change of -25.9% year over year.International Revenue- Total ablation: $12.71 million compared to the $14.54 million average estimate based on three analysts. The reported number represents a change of +7% year over year.United States Revenue- Total: $109.31 million versus $106.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.5% change.International Revenue- Appendage management: $10.17 million compared to the $10.58 million average estimate based on three analysts. The reported number represents a change of +18.5% year over year.United States Revenue- Open ablation: $35.59 million compared to the $34.88 million average estimate based on three analysts. The reported number represents a change of +16.3% year over year.International Revenue- Open ablation: $10.85 million compared to the $9.73 million average estimate based on three analysts. The reported number represents a change of +26.1% year over year.United States Revenue- Minimally invasive ablation: $7.43 million versus the three-analyst average estimate of $7.94 million. The reported number represents a year-over-year change of -33.2%.International Revenue- Minimally invasive ablation: $1.86 million versus $2.04 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change.United States Revenue- Appendage management: $45.45 million versus the three-analyst average estimate of $43.06 million. The reported number represents a year-over-year change of +21.5%.International Revenue- Total: $24.96 million versus $25.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +22% change.View all Key Company Metrics for AtriCure here>>>Shares of AtriCure have returned +3.4% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AtriCure, Inc. (ATRC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks